Discovering Asia's Undiscovered Gems in October 2025

As global markets navigate a complex landscape marked by economic uncertainties and shifting monetary policies, Asian small-cap stocks are capturing attention for their potential resilience and growth. In this environment, identifying promising opportunities requires a keen eye for companies with strong fundamentals and the ability to adapt to changing market conditions.

Top 10 Undiscovered Gems With Strong Fundamentals In Asia

Click here to see the full list of 2383 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.

We're going to check out a few of the best picks from our screener tool.

Viva Biotech Holdings (SEHK:1873)

Simply Wall St Value Rating: ★★★★★☆

Overview: Viva Biotech Holdings is an investment holding company that offers structure-based drug discovery services to biotechnology and pharmaceutical clients globally, with a market capitalization of HK$6.01 billion.

Operations: Viva Biotech Holdings generates revenue primarily from its Drug Discovery Services and Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, with the latter contributing CN¥995.92 million. The company's net profit margin shows notable trends that could be of interest to investors analyzing its financial performance.

Viva Biotech Holdings, a nimble player in the life sciences sector, recently joined the S&P Global BMI Index. This company has shown resilience by turning profitable last year and maintaining a satisfactory net debt to equity ratio of 5.7%. Despite earnings forecasted to dip by 35.1% annually over three years, revenue is expected to rise by 15.72% each year. The price-to-earnings ratio stands at an attractive 31.9x compared to the industry average of 52.4x, suggesting potential value for investors seeking growth opportunities in this space. Recent buybacks totaling HKD 30.49 million underscore confidence in future prospects.

• Click here and access our complete health analysis report to understand the dynamics of Viva Biotech Holdings.

• Understand Viva Biotech Holdings' track record by examining our Past report.

Jiangxi Jiangnan New Material Technology (SHSE:603124)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Jiangxi Jiangnan New Material Technology Co., Ltd. operates in the new materials sector and has a market capitalization of CN¥12.70 billion.

Operations: The company generates revenue primarily through its operations in the new materials sector.

Jiangxi Jiangnan New Material Technology, a promising player in the materials sector, reported half-year sales of CNY 4.82 billion, up from CNY 4.11 billion the previous year. Despite net income rising to CNY 105.59 million from CNY 98.33 million, earnings per share slightly decreased to CNY 0.83 from CNY 0.9 due to increased shares outstanding or other factors not specified here. The company's debt profile is strong with a satisfactory net debt to equity ratio of 12%, and its interest payments are well-covered by EBIT at a ratio of 6.8x, indicating robust financial management amidst industry volatility and growth challenges in free cash flow generation.

• Navigate through the intricacies of Jiangxi Jiangnan New Material Technology with our comprehensive health report here.

• Learn about Jiangxi Jiangnan New Material Technology's historical performance.

Shenzhen Injoinic TechnologyLtd (SHSE:688209)

Simply Wall St Value Rating: ★★★★★★

Overview: Shenzhen Injoinic Technology Co., Ltd. is an IC design company that focuses on designing, developing, manufacturing, and selling digital-analog hybrid chips with a market capitalization of CN¥9.74 billion.

Operations: Injoinic's primary revenue stream comes from its integrated circuit segment, generating CN¥1.51 billion. The company's financial performance is highlighted by a notable gross profit margin trend that reflects its operational efficiency and cost management strategies.

Shenzhen Injoinic Technology, a small player in the semiconductor space, has shown impressive earnings growth of 106.7% over the past year, outpacing the industry average of 10.4%. Despite this surge, it's trading at a notable 38.7% below its estimated fair value. The company's recent half-year results reveal sales climbing to CNY 698 million from last year's CNY 601 million and net income rising to CNY 51.92 million from CNY 39.05 million previously. With no debt on its balance sheet and high-quality earnings reported, it seems well-positioned for future opportunities in its sector.

• Get an in-depth perspective on Shenzhen Injoinic TechnologyLtd's performance by reading our health report here.

• Examine Shenzhen Injoinic TechnologyLtd's past performance report to understand how it has performed in the past.

Make It Happen

• Explore the 2383 names from our Asian Undiscovered Gems With Strong Fundamentals screener here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com